X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.ema.europa.eu/en/documents/overview/tavneos-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/tavneos-avacopan-included-in-updated-eular-recommendations-for-the-management-of-aav-301782385.html
https://www.ema.europa.eu/en/documents/overview/tavneos-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/tavneos-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2022/08/24/2503784/19219/en/ChemoCentryx-Announces-TAVNEOS-avacopan-Presentations-at-Upcoming-Medical-Conferences.html
https://www.globenewswire.com/news-release/2022/05/11/2440829/19219/en/ChemoCentryx-Announces-Upcoming-Conference-Abstracts-Focused-on-TAVNEOS-avacopan-and-the-Burden-of-Systemic-Glucocorticoid-Use-in-ANCA-Associated-Vasculitis.html
https://www.globenewswire.com/news-release/2022/01/19/2369344/19219/en/ChemoCentryx-Announces-EU-Approval-of-TAVNEOS-avacopan-for-the-Treatment-of-ANCA-Associated-Vasculitis.html
https://www.globenewswire.com/news-release/2021/11/04/2327520/19219/en/Abstracts-at-the-Annual-Meetings-of-the-American-Society-of-Nephrology-and-American-College-of-Rheumatology-Highlight-Potential-Value-of-TAVNEOS-avacopan.html
https://www.clinicaltrialsarena.com/news/company-news/coverage-restrictions-likely-to-apply-to-recently-approved-anca-vasculitis-drug/
https://www.prnewswire.com/news-releases/pantherx-rare-pharmacy-selected-by-chemocentryx-to-distribute-tavneos-avacopan-in-antineutrophil-cytoplasmic-antibody-anca-associated-vasculitis-301400605.html
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-drug-adults-rare-form-blood-vessel-inflammation#:~:text=FDA%20has%20approved%20Tavneos%20(avacopan,autoantibody%20(ANCA)%2Dassociated%20vasculitis.
https://www.businesswire.com/news/home/20211013005817/en/Amber-Specialty-Pharmacy-Selected-by-ChemoCentryx-to-Dispense-TAVNEOS%E2%84%A2-avacopan-an-Adjunctive-Treatment-for-ANCA-Associated-Vasculitis
https://www.globenewswire.com/news-release/2021/07/06/2258260/19219/en/ChemoCentryx-Announces-Filing-of-Amendment-to-NDA-Submission-and-Extension-of-the-PDUFA-Review-Period-for-Avacopan-in-the-Treatment-of-ANCA-Associated-Vasculitis.html
https://www.globenewswire.com/news-release/2021/06/08/2243635/19219/en/ChemoCentryx-Announces-Abstract-on-Avacopan-in-ANCA-Associated-Vasculitis-Selected-as-One-of-the-Ten-Best-Abstracts-at-the-ERA-EDTA-Congress.html
https://ir.chemocentryx.com/news-releases/news-release-details/chemocentryx-submits-new-drug-application-us-fda-avacopan-anca
http://www.globenewswire.com/news-release/2020/06/03/2042821/0/en/ChemoCentryx-Phase-III-ADVOCATE-Trial-of-Avacopan-in-ANCA-Associated-Vasculitis-Highlighted-in-Oral-Plenary-Presentations-at-EULAR-and-ERA-EDTA-Congresses.html
https://www.biospace.com/article/chemocentryx-shares-rocket-300-percent-at-positive-vasculitis-trial-data/?s=95
https://www.fiercebiotech.com/biotech/chemocentryx-pulls-conditional-approval-filing-to-rejig-regulatory-plan
https://www.ema.europa.eu/documents/medicine-qa/questions-answers-withdrawal-marketing-authorisation-application-vynpenta-avacopan_en.pdf
Market Place
Share 
